Virtu Financial LLC Invests $605,000 in Greenwich LifeSciences, Inc. $GLSI

Virtu Financial LLC purchased a new stake in shares of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 28,797 shares of the company’s stock, valued at approximately $605,000.

Other large investors have also recently modified their holdings of the company. Bank of America Corp DE grew its stake in Greenwich LifeSciences by 22.3% in the fourth quarter. Bank of America Corp DE now owns 7,262 shares of the company’s stock worth $82,000 after purchasing an additional 1,322 shares in the last quarter. Strs Ohio bought a new stake in Greenwich LifeSciences during the 1st quarter valued at $177,000. Rhumbline Advisers lifted its holdings in shares of Greenwich LifeSciences by 48.7% in the 1st quarter. Rhumbline Advisers now owns 9,673 shares of the company’s stock worth $92,000 after buying an additional 3,168 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Greenwich LifeSciences by 1.4% in the 2nd quarter. Geode Capital Management LLC now owns 138,982 shares of the company’s stock worth $1,261,000 after buying an additional 1,972 shares during the period. Finally, Marshall Wace LLP bought a new position in shares of Greenwich LifeSciences during the 2nd quarter worth $509,000. Hedge funds and other institutional investors own 4.16% of the company’s stock.

Greenwich LifeSciences Price Performance

Shares of GLSI stock opened at $23.75 on Tuesday. The stock’s 50-day moving average is $24.88 and its 200 day moving average is $23.63. Greenwich LifeSciences, Inc. has a 1-year low of $7.78 and a 1-year high of $34.10. The company has a market cap of $348.65 million, a P/E ratio of -15.13 and a beta of 1.40.

Analyst Ratings Changes

Several equities analysts have recently commented on the company. Wall Street Zen lowered Greenwich LifeSciences from a “hold” rating to a “sell” rating in a research note on Saturday, June 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Greenwich LifeSciences in a research report on Friday, May 15th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $47.50.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc (NASDAQ: GLSI) is a clinical-stage biotechnology company focused on the development of novel immune modulators for the treatment of cancer and autoimmune diseases. The company’s product pipeline includes candidates engineered to activate or regulate key components of the innate and adaptive immune systems, with programs advancing through preclinical and early-stage clinical studies.

Headquartered in Greenwich, Connecticut, Greenwich LifeSciences conducts its research and development activities primarily in the United States.